Ann: Invex Receives Written Response from FDA on Type C Meeting, page-42

Really hope management just push ahead with Europe trial.

As I previously suspected, the ambiguity of that announcement is warning enough that the market hasn't priced in the two trials.

Unless management are comfortable trying to raise further capital at somewhere in the 40 cent range (further dilution), then they need to push ahead solely with Europe, get some positive movement back into the stock and show-off the real world benefits of this drug.

I'll top up on news of a Europe only trial, or in the very unlikely scenario that the FDA is happy with one trial. I'll be selling on any news of the double trial and just take the losses.